Protalix BioTherapeutics, Inc. (PLX) Short-Term Debt to Capital

The market valuation dynamics for Protalix BioTherapeutics (PLX) on the GURU.Markets platform, which currently stands at 0.01, are driven by the eco-friendly production of plant-cell-based drugs with minimal environmental impact. Growth is supported by the global rollout of the first approved therapy for rare pathologies through partnerships with industry behemoths. The ProCellEx system provides a competitive advantage by eliminating viral threats and reducing protein production costs.

Fundamental asset screening requires an accurate liquidity assessment to determine an issuer's stability. By analyzing the current short-term debt-to-equity ratio, an investor compares obligations maturing within one year against the company's own funds to identify reliance on costly refinancing. A low metric value minimizes financial risks. For Protalix BioTherapeutics (PLX), this is critical when developing niche innovations and refining its protein expression platform.